Effects of treatment with dexamethasone or dexamethasone plus rituximab on the rates of sustained response (overall SR: platelet count ≥ 50 × 109/L; SR 100: platelet count ≥ 100 × 109/L; SR 150: platelet count ≥ 150 × 109/L)
| Patients . | SR . | SR 100 . | SR 150 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Platelets 50 × 109/L or greater . | Platelets 100 × 109/L or greater . | Platelets 150 × 109/L or greater . | |||||||
| Dexamethasone . | Dexamethasone plus rituximab . | P . | Dexamethasone . | Dexamethasone plus rituximab . | P . | Dexamethasone . | Dexamethasone plus rituximab . | P . | |
| Evaluable | 52 | 49 | 52 | 49 | 52 | 49 | |||
| Responders, n (%) | 19 (36) | 31 (63) | .004 | 17 (33) | 26 (53) | .019 | 13 (25) | 21 (43) | .029 |
| Patients . | SR . | SR 100 . | SR 150 . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Platelets 50 × 109/L or greater . | Platelets 100 × 109/L or greater . | Platelets 150 × 109/L or greater . | |||||||
| Dexamethasone . | Dexamethasone plus rituximab . | P . | Dexamethasone . | Dexamethasone plus rituximab . | P . | Dexamethasone . | Dexamethasone plus rituximab . | P . | |
| Evaluable | 52 | 49 | 52 | 49 | 52 | 49 | |||
| Responders, n (%) | 19 (36) | 31 (63) | .004 | 17 (33) | 26 (53) | .019 | 13 (25) | 21 (43) | .029 |
SR indicates sustained response; SR 100, SR of platelet count ≥ 100 × 109/L; and SR 150, SR of platelet count ≥ 150 × 109/L.